GILD
Gilead Sciences IncNASDAQ
Healthcare • Drug Manufacturers - General
Updated 1 day ago
Coverage limited
Factor tilt: Growth-tilted Large Cap
$147.92-1.67%
Close Oct 13, 2026
- Market cap
- $183.65B
- 1 month
- +1.0%
- 3 months
- +12.3%
- 1 year
- +26.2%
- 52-week range
- $117.85$155.80
- Dividend, last 12 mo
- $3.25 · 2.20% yield
- Last ex-date
- Sep 15, 2026 · $0.82
- Dividend growth
- 10+ years in a row
- Next-quarter EPS estimate
- $2.15Quarter to Sep 30, 2026 · 22 analysts · revenue $7.77B
- Short interest
- 1.8% of float21.8M shares · settled Sep 30, 2026 · +19.3% since Sep 15, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $30.46B
- Net income
- -$3.24B
- Free cash flow
- $13.2B
- Book value
- $11.83B
- Total debt
- $26.25B
- P/E
- —
- Price / sales
- 6×
- Price / book
- 15.5×
- FCF yield
- +7.2%
- Net margin
- -10.6%
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Portfolio context
Sign in to see your position size
We’ll show you if GILD is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
Smart money context
Holder IQ: MEDIUM
293 top institutions tracked
as of 2026-Q2 (filed 2026-09-29)
Last 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: bearish
Last trade: sell 12 days ago
Red flags: 0
Largest 13-F holders · Q2 2026
2,291 filers reported a long position in GILD for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| BlackRock, Inc. | $15.4B | 121.8M | +2.4% |
| VANGUARD CAPITAL MANAGEMENT LLC | $10.2B | 81.1M | +0.5% |
| FMR LLC | $8.4B | 66.9M | -7% |
| STATE STREET CORP | $7.7B | 61.2M | +2.3% |
| Capital World Investors | $5.2B | 41M | -0.7% |
| Invesco Ltd. | $5B | 39.8M | -4.2% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $4.5B | 35.3M | +0.5% |
| GEODE CAPITAL MANAGEMENT, LLC | $3.8B | 30.1M | +1.1% |
| PRICE T ROWE ASSOCIATES INC /MD/ | $3.8B | 30M | +14.3% |
| MORGAN STANLEY | $3B | 24M | +3% |
Get the Full Analysis for GILD
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.